Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Canaan VIII, L.P., an investment fund associated with Liquidia director Stephen M. Bloch, sold 70,234 shares of Liquidia common stock in open-market transactions. The sales occurred on March 26–27 at weighted average prices ranging from about $35 to $37 per share across several trades.
After these sales, entities tied to the fund reported holding 2,188,935 shares indirectly, while Bloch also reported 65,712 shares held directly. Bloch disclaims beneficial ownership of the fund-held shares except for his pecuniary interest and did not participate in the investment decision due to a communications-screen policy.
Canaan VIII LP filed a Form 144 disclosing a proposed sale of 62,550 shares of Common Stock. The filing lists UBS Financial Services as the broker and records a prior sale of 7,684 shares on 03/26/2026.
Liquidia Corp Chief Commercial Officer Scott Moomaw exercised stock options and sold shares in a planned transaction. He exercised options to acquire 17,000 shares of common stock at $3.40 per share, then sold 17,000 shares at a volume-weighted average price of $36.8128 and an additional 1,314 shares at $36.48 in open-market trades.
The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on November 7, 2025, and represent the sale of shares underlying fully vested options. After these trades, he holds 187,640 shares directly, and his reported holdings include multiple tranches of unvested RSUs and 2,650 shares acquired under the employee stock purchase plan.
Liquidia Corp’s Chief Medical Officer Rajeev Saggar sold 35,365 shares of Common Stock in an open-market transaction. The shares were sold on March 13, 2026 at a volume-weighted average price of $36.3024, based on trades between $36.29 and $36.45.
After the sale, Saggar directly holds 174,473 shares of Liquidia, which include multiple blocks of unvested restricted stock units granted in 2023, 2024, and 2025, additional RSUs granted in 2026 that have not yet vested, and 2,213 shares acquired under the 2020 Employee Stock Purchase Plan.
Liquidia Corp’s Chief Human Resource Officer, Sarah Krepp, reported an open-market sale of 16,261 shares of common stock at $38.00 per share. After this transaction, she directly holds 148,397 common shares. Her holdings also include various unvested RSU awards and shares acquired under the company’s employee stock purchase plan.
Liquidia Corp director Raman Singh reported an option exercise followed by a share sale. Singh exercised non-qualified stock options for 20,000 shares of Common Stock at $4.86 per share and then sold 20,000 shares on the same date at a volume-weighted average price of $36.0414.
After these transactions, Singh directly owned 38,755 shares of Common Stock, plus 18,396 restricted stock units granted on June 17, 2025, which had not vested as of this Form 4. The filing also corrects a prior administrative error by acknowledging an earlier exercise of options for 7,500 shares that had been omitted from a previous Form 4, although that earlier sale was disclosed.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell common stock of LQDA. The filing lists 20,359 restricted shares with an intended sale date of 06/16/2025 and a 20,000 share stock option exercise dated 03/13/2026 (cash exercise).
The entry shows a combined figure of 40,359 shares in the excerpted rows and indicates NASDAQ as the market; the filing is routine disclosure under Rule 144.
LQDA reported an insider sale via Form 144. The filing shows Rajeev Saggar sold 21,142 shares of Common Stock on 01/12/2026 for $791,304.89. The submission also lists multiple prior restricted stock issuances with dates and share counts.
Sarah T. Krepp reported sale notices on Form 144 for common stock. The filing lists two reported dispositions: 276 shares sold on 03/02/2026 for $8,440.85 and 13,165 shares sold on 01/12/2026 for $492,740.94.
The excerpt also lists securities identified as to be sold by the issuer on 01/11/2026: Restricted Stock amounts 1,634, 7,087, and 395, and Performance Shares 7,145.